

## 2017 Bayer Hematology Conference: Redefining Protection in Hemophilia

Thursday, November 2 – Saturday, November 4, 2017

Hilton Amsterdam Airport Schiphol, The Netherlands

Steering Committee:

- Chair: Roger Schutgens | Netherlands
  - Co-chair: Elena Santagostino | Italy
  - Shannon Jackson | Canada
- Shadan Lalezari | Israel
  - Philippe Nguyen | France
  - Pia Petrini | Sweden

| Thursday, November 2, 2017 |   |  |
|----------------------------|---|--|
| Time                       | Topic   | Speaker                                  |
|                            | Participant and faculty arrivals  |  |
| 11:00am – 7:00pm           | Slide reviews   |  |
| 7:00pm – 10:00pm           | Faculty dinner (by invitation only)<br>Country dinners (by invitation from Bayer affiliate – to be determined by country) |  |
| Friday, November 3, 2017   |   |  |
| Time                       | Topic   | Speaker                                  |
| 9:00am – 9:05am            | Welcome   | Bayer                                    |
| 9:05am – 9:20am            | Introduction  | Roger Schutgens (Netherlands)            |
| 9:20am – 9:30am            | History of hemophilia treatment in the Netherlands  | Evelien Mauser-Bunschoten (Netherlands)  |
| <b>9:30am – 11:00am</b>    | <b>Session 1: Real Unmet Needs</b>  | <b>Chair: Shadan Lalezari (Israel)</b>   |
|                            | Intracranial hemorrhages  | Karin Fijnvandraat (Netherlands)         |
|                            | When and how to start immunosuppression in patients with inhibitors   | Elena Santagostino (Italy)               |
|                            | Aging with hemophilia: Balancing anti-thrombotics vs. coagulation   | Roger Schutgens (Netherlands)            |
|                            | Panel Discussion and Q&A  | All                                      |
| 11:00am – 11:30am          | Coffee break  |  |
| <b>11:30am – 1:10pm</b>    | <b>Session 2: Design and Technology</b>   | <b>Chair: Philippe Nguyen (France)</b>   |
|                            | Disruptive therapies in hemophilia  | John Pasi (UK)                           |
|                            | PEG and PEGylated proteins  | Andreas Baumann (Germany)                |
|                            | Anti-TFPI – mechanism   | Philippe Nguyen (France)                 |
|                            | Extravascular compartment and coagulation   | Peter Lenting (France)                   |
|                            | Panel Discussion and Q&A  | All                                      |
| 1:10pm – 2:30pm            | Lunch   |  |
| <b>2:30pm – 3:00pm</b>     | <b>Hemophilia Slam</b>  | <b>Chair: Elena Santagostino (Italy)</b> |
|                            | ABO blood group and inhibitor risk in severe hemophilia A   | Gabriele Quintavalle (Italy)             |
|                            | The Israeli PGD Experience in hemophilia  | Rima Dardik (Israel)                     |
|                            | Early signs of arthropathy  | Magnus Aspdahl (Sweden)                  |

|                                   |   |   |
|-----------------------------------|---|---|
|                                   | Experience in FDA inspections from a site perspective   | Tami Barazani-Brutman (Israel)  |
|                                   | Improving ambulation for the hemophilic patient   | Rachel Tiktinsky (Israel)   |
|                                   | Moving toward patient-centered care in hemophilia: Understanding patients' needs                    | Erna van Balen (Netherlands)  |
|                                   | Blood-induced joint damage  | Astrid Pulles (Netherlands)   |
| <b>3.00pm – 3:40pm</b>            | <b>Poster Viewing Session</b><br>Lead authors will present their research projects by their posters |   |
| <b>3:40pm – 5:20pm</b>            | <b>Session 3: Observations and Outcomes</b>   | <b>Chair: Shannon Jackson (Canada)</b>                                |
|                                   | How to measure clinical outcomes in real life   | Kathelijn Fischer (Netherlands)                                       |
|                                   | Patient reported outcomes in hemophilia   | Mark Skinner (USA)  |
|                                   | What have we learnt from observations in registries and databases?                                  | Samantha Gouw (Netherlands)   |
|                                   | Real world experience when switching  | Shannon Jackson (Canada)  |
|                                   | Panel Discussion and Q&A  |   |
| 5:20pm – 5:30pm                   | Close of Day One  | Elena Santagostino (Italy)  |
| 6:30pm                            | Depart for Conference dinner  |   |
| <b>Saturday, November 4, 2017</b> |   |   |
| 9:00am – 9:05am                   | Welcome and recap of day 1  | Elena Santagostino (Italy)  |
| 9:05am – 11:30am                  | <b>Session 4: Testing and Measurement</b>   |   |
|                                   | Workshop Introduction on Pharmacokinetics   | Alfonso Iorio (Canada)  |
|                                   | <b>Case Studies Workshops</b>   |   |
|                                   | <b>Workshop 1</b><br>Alfonso Iorio (Canada)   | <b>Workshop 3</b><br>Waander van Heerde (Netherlands)                 |
|                                   | <b>Workshop 2</b><br>Siv Jönsson (Sweden)<br>Erik Berntorp (Sweden)                                 | <b>Workshop 4</b><br>Michael Steiner (Germany)<br>Jan Pilch (Germany) |
| 10:35am – 11:00am                 | Coffee break  |   |
|                                   | Workshop Feedback and Q&A   |   |
| <b>11:30am – 1:20pm</b>           | <b>Session 5: Increasing protection</b>   | <b>Chair: Pia Petrini (Sweden)</b>                                    |
|                                   | Advanced prophylaxis to protect from non-visible bleeds   | Pia Petrini (Sweden)  |
|                                   | Increasing protection by switching to EHL   | Andreas Tiede (Germany)   |
|                                   | Medical ethics and considerations for gene therapy  | Annelien Bredenoord (Netherlands)                                     |
|                                   | Gene therapy  | Amit Nathwani (UK)  |
|                                   | Panel Discussion and Q&A  | All   |
| 1:20pm – 1:25pm                   | Poster Award Ceremony   | Shadan Lalezari (Israel)  |
| 1:25pm – 1.30pm                   | Conference close: Redefining Protection in Hemophilia   | Roger Schutgens (Netherlands)   |
| 1.30pm onwards                    | Closing remarks, lunch and departures   |   |